Skip to main content
Top
Published in: Acta Diabetologica 6/2013

01-12-2013 | Original Article

“Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL

Authors: Antonio Lacquaniti, Valentina Donato, Basilio Pintaudi, Giacoma Di Vieste, Valeria Chirico, Antoine Buemi, Antonino Di Benedetto, Adriana Arena, Michele Buemi

Published in: Acta Diabetologica | Issue 6/2013

Login to get access

Abstract

The aim of this study was to demonstrate that neutrophil gelatinase-associated lipocalin (NGAL) increased before the onset of microalbuminuria in patients with type 1 diabetes mellitus (T1DM), representing an important biochemical parameter with high sensitivity and specificity to make a precocious diagnosis of “normoalbuminuric” diabetic nephropathy (DN). Serum NGAL (sNGAL) and urinary NGAL (uNGAL) levels were evaluated in a cohort of fifty patients affected by T1DM. They had no signs of clinical nephropathy. Thirty-five healthy subjects (HS) were recruited. sNGAL levels were significantly higher compared with those measured in HS [193.7 (103.2–405.4) vs. 46.4 (39.8–56.2) ng/ml; p < 0.0001], as were uNGAL levels [25.5 (14.2–40.2) vs. 6.5 (2.9–8.5) ng/ml; p < 0.0001]. sNGAL was found to be directly correlated with glycated hemoglobin. uNGAL also positively correlated with albuminuria, whereas an inverse correlation was found with uric acid. After multivariate analysis, significance was maintained for the correlation between uNGAL and microalbuminuria. In ROC analysis, sNGAL showed a good diagnostic profile such as uNGAL. NGAL increases in patients with T1DM, even before diagnosis of microalbuminuria representing an early biomarker of “normoalbuminuric” DN with a good sensitivity and specificity. NGAL measurement could be useful for the evaluation of early renal involvement in the course of diabetes.
Literature
1.
2.
go back to reference Fathy Manal A, Elkady Manal M, Fathy Hanan A, Awad Seham A, Elmenshawy Amal A (2009) Estimation of renal tubular markers for predicting early stage diabetic nephropathy in Egyptian children with type I diabetes mellitus. Res J Med Med Sci 4:207–211 Fathy Manal A, Elkady Manal M, Fathy Hanan A, Awad Seham A, Elmenshawy Amal A (2009) Estimation of renal tubular markers for predicting early stage diabetic nephropathy in Egyptian children with type I diabetes mellitus. Res J Med Med Sci 4:207–211
3.
go back to reference MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G (2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195–200PubMedCrossRef MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G (2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195–200PubMedCrossRef
4.
go back to reference Thomas MC, Burns WC, Cooper ME (2005) Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12:177–186PubMedCrossRef Thomas MC, Burns WC, Cooper ME (2005) Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12:177–186PubMedCrossRef
5.
go back to reference Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373PubMedCrossRef Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373PubMedCrossRef
6.
go back to reference Wolf G (2000) Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 77:59–66CrossRef Wolf G (2000) Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 77:59–66CrossRef
7.
go back to reference Pfleiderer S, Zimmerhackl LB, Kinne R, Manz F, Schuler G, Brandis M (1993) Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Investig 71:972–977PubMedCrossRef Pfleiderer S, Zimmerhackl LB, Kinne R, Manz F, Schuler G, Brandis M (1993) Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Investig 71:972–977PubMedCrossRef
8.
go back to reference Yaqoob M, McClelland P, Patrick AW et al (1994) Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM 87:601–607PubMed Yaqoob M, McClelland P, Patrick AW et al (1994) Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM 87:601–607PubMed
9.
go back to reference Dunlop M (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 77:S3–S12PubMedCrossRef Dunlop M (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 77:S3–S12PubMedCrossRef
10.
go back to reference Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–789PubMedCrossRef Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–789PubMedCrossRef
11.
go back to reference Bolignano D, Donato V, Coppolino G et al (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52:595–605PubMedCrossRef Bolignano D, Donato V, Coppolino G et al (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52:595–605PubMedCrossRef
12.
go back to reference Mishra J, Dent C, Tarabishi R et al (2005) Neutrophil gelatinase-associated lipocalin as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238PubMedCrossRef Mishra J, Dent C, Tarabishi R et al (2005) Neutrophil gelatinase-associated lipocalin as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238PubMedCrossRef
13.
go back to reference Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006) Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26:287–292PubMedCrossRef Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006) Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26:287–292PubMedCrossRef
14.
go back to reference Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M (2008) Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 31:255–258PubMedCrossRef Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M (2008) Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 31:255–258PubMedCrossRef
15.
go back to reference Bolignano D, Lacquaniti A, Coppolino G et al (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337–344PubMedCrossRef Bolignano D, Lacquaniti A, Coppolino G et al (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337–344PubMedCrossRef
16.
go back to reference Guo L, Cheng Y, Wang X et al (2012) Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality. Acta Diabetol 49:65–71CrossRef Guo L, Cheng Y, Wang X et al (2012) Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality. Acta Diabetol 49:65–71CrossRef
17.
go back to reference Bolignano D, Coppolino G, Lacquaniti A, Buemi M (2010) From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 40:273–276PubMedCrossRef Bolignano D, Coppolino G, Lacquaniti A, Buemi M (2010) From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 40:273–276PubMedCrossRef
18.
go back to reference Bolignano D, Lacquaniti A, Coppolino G et al (2009) Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 32:91–98PubMedCrossRef Bolignano D, Lacquaniti A, Coppolino G et al (2009) Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 32:91–98PubMedCrossRef
19.
go back to reference Zachwieja J, Soltysiak J, Fichna P et al (2009) Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr Nephrol 25:51–1445 Zachwieja J, Soltysiak J, Fichna P et al (2009) Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr Nephrol 25:51–1445
20.
go back to reference Soggiu A, Piras C, Bonizzi L et al (2012) A discovery-phase urine proteomics investigation in type 1 diabetes. Acta Diabetol 49:453–464PubMedCrossRef Soggiu A, Piras C, Bonizzi L et al (2012) A discovery-phase urine proteomics investigation in type 1 diabetes. Acta Diabetol 49:453–464PubMedCrossRef
21.
go back to reference Phillips AO (2003) The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 3:491–496PubMedCrossRef Phillips AO (2003) The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 3:491–496PubMedCrossRef
22.
go back to reference Mori K, Lee HT, Rapoport D et al (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115:610–621PubMed Mori K, Lee HT, Rapoport D et al (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115:610–621PubMed
23.
go back to reference Kuwabara T, Mori K, Mukoyama M et al (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules and distal nephrons. Kidney Int 75:285–294PubMedCrossRef Kuwabara T, Mori K, Mukoyama M et al (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules and distal nephrons. Kidney Int 75:285–294PubMedCrossRef
24.
go back to reference Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P (2011) Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 79:1113–1118PubMedCrossRef Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P (2011) Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 79:1113–1118PubMedCrossRef
25.
go back to reference Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33:1320–1324PubMedCrossRef Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33:1320–1324PubMedCrossRef
26.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
27.
go back to reference Fukuhara M, Matsumura K, Wakisaka M et al (2007) Hyperglycemia promotes microinflammation as evaluated by C-reactive protein in the very elderly. Intern Med 46:207–212PubMedCrossRef Fukuhara M, Matsumura K, Wakisaka M et al (2007) Hyperglycemia promotes microinflammation as evaluated by C-reactive protein in the very elderly. Intern Med 46:207–212PubMedCrossRef
28.
go back to reference Stern MP (1998) The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes. Arch Fam Med 7:155–162PubMedCrossRef Stern MP (1998) The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes. Arch Fam Med 7:155–162PubMedCrossRef
29.
go back to reference Nambi V (2005) The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 7:127–131PubMedCrossRef Nambi V (2005) The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 7:127–131PubMedCrossRef
30.
go back to reference Elneihoum AM, Falke P, Hedblad B, Lindga¨rde F, Ohlsson K (1997) Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 131:79–84PubMedCrossRef Elneihoum AM, Falke P, Hedblad B, Lindga¨rde F, Ohlsson K (1997) Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 131:79–84PubMedCrossRef
31.
go back to reference Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Pawlak K, Dobrzycki S (2008) Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology 13:153PubMedCrossRef Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Pawlak K, Dobrzycki S (2008) Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology 13:153PubMedCrossRef
32.
go back to reference Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study. Diabetes 58:1668–1671PubMedCrossRef Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study. Diabetes 58:1668–1671PubMedCrossRef
33.
go back to reference Mene P, Punzo G (2008) Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 26:2085–2092PubMedCrossRef Mene P, Punzo G (2008) Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 26:2085–2092PubMedCrossRef
34.
go back to reference Siu YP, Leung KT, Tong MKH, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability in lowering serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRef Siu YP, Leung KT, Tong MKH, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability in lowering serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRef
Metadata
Title
“Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL
Authors
Antonio Lacquaniti
Valentina Donato
Basilio Pintaudi
Giacoma Di Vieste
Valeria Chirico
Antoine Buemi
Antonino Di Benedetto
Adriana Arena
Michele Buemi
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 6/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0485-7

Other articles of this Issue 6/2013

Acta Diabetologica 6/2013 Go to the issue